Skip to Content
Skip to Navigation

Browse Faculty by
Last Name

Access your account with your UWNetID

John Amory, MD, MPH

Professor, Department of Medicine (DOM)
Section Head, University of Washington Medical Center

Education & Training

MD, University of California, San Francisco, San Francisco, CA, 1989-1994
Residency in Internal Medicine, University of California, San Francisco, San Francisco, CA, 1994-1997
MPH, University of Washington, Seattle, WA, 2004-2006

Professional Interests

Male contraception
Androgens in aging
Testosterone deficiency
Klinefelter's Syndrome
Male infertility

Honors

Dean's Prize for Medical Student Research, 1992
Martin Memorial Award for Outstanding Second-Year Medicine Resident, 1996
Weingarten Memorial Award for Outstanding Third-Year Medicine Resident , 1997
Fellowship, American College of Physicians, 2003
Alpha Omega Alpha, Honorary Inductee, 2003
Paul Beeson Award for Excellence in Housestaff Instruction, 2003
Helen and Phillip Fialkow Scholar, 2004
Endocrine Society International Award for Excellence in Published Clinical Research, 2005
Young Andrologist Award, 2007
Elected Member, American Society of Clinical Investigation, 2013

Selected Publications

Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover LJ. 2004. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. The Journal of clinical endocrinology and metabolism. 89(2):503-10.
Amory JK, Bremner WJ. 2005. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. The Journal of clinical endocrinology and metabolism. 90(5):2610-7.
Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. 2007. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. The Journal of clinical endocrinology and metabolism. 92(5):1659-65.
Amory JK, Leonard TW, Page ST, O'Toole E, McKenna MJ, Bremner WJ. 2009. Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer chemotherapy and pharmacology. 64(3):641-5.
Amory JK, Muller CH, Shimshoni JA, Isoherranen N, Paik J, Moreb JS, Amory DW, Evanoff R, Goldstein AS, Griswold MD. 2011. Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. Journal of andrology. 32(1):111-9.